Pyridine Or Partially Hydrogenated Pyridine Rings Are Bonded Directly To Each Other Patents (Class 546/257)
  • Patent number: 10307410
    Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 4, 2019
    Assignees: CENTRE REGIONAL DE LUTTE CONTRE LE CANCER FRANCOIS BACLESSE, UNIVERSITE DE CAEN BASSE-NORMANDIE, INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Inventors: Laurent Poulain, Anne-Sophie Voisin-Chiret, Jana Sopkova-de Oliveira Santos, Ronan Bureau, Grégory Burzicki, Marcella De Giorgi, Serge Perato, Jade Fogha, Sylvain Rault, Philippe Juin, Fabien Gautier
  • Patent number: 9603931
    Abstract: The present invention relates to a macromolecule for delivering protein, polypeptide or peptide drugs and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs comprising the same, and more specifically relates to a polylactic acid derivative compound of Chemical formula 1 of which the numerical average molecular weight is no more than 7000 daltons and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs using the same and to a production method for the same.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: March 28, 2017
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Yil Woong Yi, Min Hyo Seo, Bong Oh Kim, In Ja Choi, Hye Jeong Yoon, Se Yoon Kim, Sang Jun Lee, Joong Woong Cho
  • Patent number: 9409881
    Abstract: There are described 6?-phenyl-2,2?-bipyridine-3-carboxylic acid derivatives of the general formula (I) as herbicides. In this formula (I), R1 to R5 are radicals such as hydrogen, organic radicals such as alkyl, and other radicals such as halogen, nitro, cyano and formyl.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: August 9, 2016
    Assignee: Bayer CropScience AG
    Inventors: Michael Gerhard Hoffmann, Uwe Doeller, Marco Bruenjes, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Dirk Schmutzler
  • Patent number: 9315489
    Abstract: The present invention relates to compounds of formula I: in which Y, Y1, Y4, Y5, Y6, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 19, 2016
    Assignee: Novartis AG
    Inventors: Pascal Furet, Robert Martin Grotzfeld, Wolfgang Jahnke, Darryl Brynley Jones, Paul William Manley, Andreas Marzinzik, Saliha Moussaoui, Xavier Francois Andre Pelle, Bahaa Salem, Joseph Schoepfer
  • Patent number: 9187428
    Abstract: The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: November 17, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Alexandros Vakalopoulos, Daniel Meibom, Peter Nell, Frank Sussmeier, Barbara Albrecht-Kupper, Katja Zimmermann, Joerg Keldenich, Dirk Schneider, Ursula Krenz
  • Patent number: 9145391
    Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: September 29, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Denis Deschenes, Michael D. Altman, John Michael Ellis, Christian Fischer, Andrew M. Haidle, Solomon D. Kattar, Alan B. Northrup, Adam J. Schell, Graham F. Smith, Brandon M. Taoka, Corey Bienstock, Maria Emilia Di Francesco, Anthony Donofrio, Scott Peterson, Kerrie B. Spencer, James Patrick Jewell, Amjad Ali, David Jonathan Bennett, Qun Dang, John Wai
  • Patent number: 9096574
    Abstract: The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy.
    Type: Grant
    Filed: January 1, 2013
    Date of Patent: August 4, 2015
    Assignee: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • Patent number: 9085532
    Abstract: The present invention relates to a process for preparing a ketosulfone derivative and, more particularly, to an improved method for synthesizing 1-(6-methylpyridin-3-yl)-2-[(4-methylsulfonyl)-phenyl]ethanone by means of Pd-catalized alpha arylation process of a heteroaromatic ketone derivative.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: July 21, 2015
    Assignee: ZACH SYSTEM S.P.A.
    Inventors: Elisa Melotto, Ivan Michieletto, Vincenzo Frega, Livius Cotarca, Massimo Verzini, Franco Massaccesi, Ilaria Munari
  • Patent number: 9024033
    Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical foimulation for the inhibition of malaria parasite proliferation.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: May 5, 2015
    Assignee: MMV Medicines for Malaria Venture
    Inventors: Michael John Witty, David Hardick
  • Patent number: 8981096
    Abstract: The design and synthesis of six nickel charge transfer (CT) complexes are described herein. The six nickel CT complexes have a nickel center, two organic ligands coordinated with the nickel center to form a dianionic square planar supramolecule and an organic counter-cation as represented by The ligands and counter-cations are selected to optimize properties, such as molecular alignment, film morphology, and molecular packaging. Described herein, the ligands can be 2,3-pyrazinedithiol (L1), 1,2-benzenedithol (L2) or 2,3-quinoxalinedithol (L3) and the counter-cations can be diquat (2,2?-ebpy) or methyl viologen (4,4?-mbpy). The six nickel CT complexes can also be utilized semiconductor devices, such as thin film transistors or inverters. Processes are also provided for the fabrication of semiconductors devices. The processes can include fabricating a substrate with a bilayer octadecylphosphonic acid (ODPA)/Al2O3 dielectric and applying one of the six nickel charge transfer (CT) complexes to the substrate.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: March 17, 2015
    Assignee: City University of Hong Kong
    Inventors: Vellaisamy A. L. Roy, Zong-Xiang Xu, Paul Kim Ho Chu, Tat Kun Kwok
  • Publication number: 20150072396
    Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: March 12, 2015
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
  • Patent number: 8962977
    Abstract: The present invention provides novel dyes for dye sensitized photovoltaic conversion devices. The dyes contain novel anchoring ligands, which have a vinyl or phenylethenyl moiety incorporated in the anchoring bipyridine. Such dyes exhibit an increased molar extinction coefficient and enhanced red response in the visible regions.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: February 24, 2015
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Mohammad Nazeeruddin, Michael Graetzel
  • Publication number: 20150031708
    Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.
    Type: Application
    Filed: May 9, 2008
    Publication date: January 29, 2015
    Inventors: Sara Hadida-Ruah, Mark Miller, Brian Bear, Jinglan Zhou, Jason McCartney, Peter Grootenhuis
  • Publication number: 20150011551
    Abstract: Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 8, 2015
    Applicant: Sanford- Burnham Medical Reseach Institute
    Inventors: Anthony B. Pinkerton, Russell Dahl, Nicholas D.P. Cosford, Jose Luis Millan
  • Publication number: 20140371273
    Abstract: The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy.
    Type: Application
    Filed: January 1, 2013
    Publication date: December 18, 2014
    Applicant: MAPI PHARMA LTD.
    Inventors: Ehud Marom, Shai Rubnov
  • Publication number: 20140357670
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: May 28, 2014
    Publication date: December 4, 2014
    Inventors: Saleem Ahmad, Lidet A. Negash
  • Publication number: 20140343042
    Abstract: The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward ?7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to ?7 nAChRs.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 20, 2014
    Inventors: William R. Kem, Ferenc Soti, Hong Xing
  • Patent number: 8889690
    Abstract: The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 18, 2014
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Publication number: 20140286927
    Abstract: A engineered composition and method of delivery of said composition providing effective therapy for the treatment of ulcerative colitis, and Crohn's disease.
    Type: Application
    Filed: June 19, 2012
    Publication date: September 25, 2014
    Inventor: Peter Edward Smith
  • Patent number: 8841451
    Abstract: The invention relates to the formation of synthesized fractal constructs and the methods of chemical self-assembly for the preparation of a non-dendritic, nano-scale, fractal constructs or molecules. More particularly, the invention relates to fractal constructs formed by molecular self-assembly, to create synthetic, nanometer-scale fractal shapes. In an embodiment, a nanoscale Sierpinski hexagonal gasket is formed. This non-dendritic, perfectly self-similar fractal macromolecule is comprised of bisterpyridine building blocks that are bound together by coordination to (36) Ru and (6) Fe ions to form a nearly planar array of increasingly larger hexagons around a hollow center.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 23, 2014
    Assignee: The University of Akron
    Inventors: George R. Newkome, Charles N. Moorefield
  • Publication number: 20140275080
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Michael D. Kaufman, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Karen M. Yates
  • Publication number: 20140271543
    Abstract: New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: July 23, 2012
    Publication date: September 18, 2014
    Applicant: ALMIRALL, S.A.
    Inventors: Paul Robert Eastwood, Jordi Bach Taña, Lluis Miquel Pages Santacana
  • Publication number: 20140239273
    Abstract: An anthracene derivative is represented by a formula (1) below, in which at least one of Ar1, Ar2, Ar3, L1, L2 and L3 is a group derived from a skeleton represented by a formula (10) below,
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: IDEMITSU KOSAN CO., LTD.
    Inventors: Sayaka MIZUTANI, Takayasu Sado
  • Publication number: 20140243337
    Abstract: The invention provides certain phenyl carboxamide-containing compounds of the Formula (I); or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 28, 2014
    Inventors: Michael D. Altman, Maria Emilia Di Francesco, John Michael Ellis, Sandra Lee Knowles, Alan B. Northrup
  • Publication number: 20140235652
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CPY17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Application
    Filed: November 13, 2013
    Publication date: August 21, 2014
    Applicant: Endo Pharmaceuticals Inc.
    Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Publication number: 20140235637
    Abstract: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: InterMune, Inc.
    Inventors: Karl Kossen, Scott D. Seiwert, Vladimir Serebryany, Donald Ruhrmund, Leonid D. Beigelman, Luca Francesco Mario Raveglia, Stefania Vallese, Ivana Bianchi, Tao Hu
  • Publication number: 20140209872
    Abstract: A compound having an electron injection capability and/or electron transport capability represented by Formula 1, an organic light emitting device including the compound; and a flat display device including the organic light emitting device. The descriptions of substituents are referred to in the detailed description.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 31, 2014
    Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Patent number: 8772497
    Abstract: The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: July 8, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Itaru Arimoto, Satoshi Nagato, Yukiko Sugaya, Yoshio Urawa, Koichi Ito, Hiroyuki Naka, Takao Omae, Akio Kayano, Katsutoshi Nishiura
  • Publication number: 20140167007
    Abstract: A pyrene-based compound and an organic light-emitting diode including the pyrene-based compound are provided.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 19, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jun-Ha Park, Eun-Young Lee, Chang-Ho Lee, Jong-Hyuk Lee
  • Publication number: 20140171449
    Abstract: The present disclosure provides pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4, R5, X and Y are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.
    Type: Application
    Filed: January 7, 2014
    Publication date: June 19, 2014
    Applicant: CONFLUENCE LIFE SCIENCES INC.
    Inventors: Shaun R. Selness, Joseph B. Monahan, John F. Schindler, Balekudru Devadas
  • Publication number: 20140166921
    Abstract: Disclosed is a double-center bipyridyl cationic ion liquid prepared by reacting bipyridyl with haloalkane for synthesis of dialkyl bipyridyl halide, and converting the halogen ion in the dialkyl bipyridyl halide to the target anion via an ion-exchange reaction, to give the final target ionic liquid. Also disclosed are an organic electrolyte containing the double-center bipyridyl cationic ion liquid and a preparation method therefor.
    Type: Application
    Filed: August 30, 2011
    Publication date: June 19, 2014
    Inventors: Mingjie Zhou, Daxi Liu, Yaobing Wang
  • Patent number: 8748582
    Abstract: The present invention relates generally to affinity ligands and chemical affinity ligand-matrix conjugates for use as chromatographic adsorbents and methods which utilize the adsorbents in the purification of proteins by affinity chromatography. The affinity ligand-matrix conjugates of the present invention comprise ligands of general formula (I): wherein m represents an integer from 0-2, n represents an integer from 0-6, p represents an integer from 0-4, R1 represents H or C1-3 alkyl, R2 is an optional substituent, and X is the position at which the ligand is immobilized, optionally via a linker.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: June 10, 2014
    Assignee: Monash University
    Inventors: Milton T W Hearn, Anjali Makarand Bhagwat, William Roy Jackson, Simon John Mountford
  • Publication number: 20140155401
    Abstract: The present invention relates to novel substituted 2,4?- and 3,4?-bipyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Peter NELL, Walter Hübsch, Barbara ALBRECHT-KÜPPER, Jörg KELDENICH, Andreas KNORR
  • Publication number: 20140142315
    Abstract: The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Itaru ARIMOTO, Satoshi NAGATO, Yukiko SUGAYA, Yoshio URAWA, Koichi ITO, Hiroyuki NAKA, Takao OMAE, Akio KAYANO, Katsutoshi NISHIURA
  • Publication number: 20140142314
    Abstract: The present disclosure provides for an expression system for the production of blue pigment indigoidine. The system comprises a heterologous host cell, a DNA sequence encoding a Sc-IndB protein, and a DNA sequence encoding a Sc-IndC protein. The system may be configured for the co-expression of the Sc-IndB and Sc-IndC. DNA sequences encoding the Sc-IndB and Sc-IndC may be provided on at least one vector. Alternatively, the DNA sequences encoding the Sc-IndB and Sc-IndC may optionally be integrated into the genome of the heterologous host genome. The expression system may further comprise a sfp gene or a PPTase.
    Type: Application
    Filed: November 14, 2013
    Publication date: May 22, 2014
    Applicant: UTAH STATE UNIVERSITY
    Inventor: Jixun Zhan
  • Publication number: 20140135328
    Abstract: The present invention relates to compounds of the formula I, wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning
  • Patent number: 8722208
    Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of high driving stability, and of a simple structure. The organic EL device is constituted of an anode, organic layers containing a phosphorescent light-emitting layer, and a cathode piled one upon another on a substrate and a phosphine oxide derivative represented by general formula (1) is contained in a phosphorescent light-emitting layer, an electron-transporting layer, a hole-blocking layer, or an exciton-blocking layer. In general formula (1), L1 is a direct bond or an aromatic group with a valence of 1-3 and Ar1 is an aromatic group. The two Ar1 groups linked to the same nitrogen atom may form a nitrogen heterocycle and may further form a fused ring together with the said nitrogen heterocycle.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: May 13, 2014
    Assignee: Nippon Steel & Sumikin Chemical Co., Ltd.
    Inventors: Takahiro Kai, Hideki Tanaka, Mitsuru Suda, Toshihiro Yamamoto, Megumi Matsumoto
  • Publication number: 20140128571
    Abstract: Compounds useful as nutritional supplements, antioxidants, heavy metal chelators and/or as intermediates for producing other related compounds with like uses have a formula: where R1 is an aromatic backbone and R2 is a sulfur containing ligand.
    Type: Application
    Filed: January 6, 2014
    Publication date: May 8, 2014
    Applicant: THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Boyd E. Haley, Niladri Narayan Gupta
  • Patent number: 8709129
    Abstract: The invention relates to novel compounds which are useful as ligands of actinides, to the synthesis of these compounds and to their uses. These compounds fit the general formula (I) hereafter: wherein R1 and R2, either identical or different, represent H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl, benzyl, diphenyl or tolyl group; R3 represents H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl, tolyl or linear or branched C1-C12 alkoxy group; while R4 represents H, a linear or branched, saturated or unsaturated C1-C12 hydrocarbon group, a phenyl or tolyl group. Field of applications: the processing of used nuclear fuels via a hydrometallurgical route.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: April 29, 2014
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Cécile Marie, Manuel Miguirditchian, Julia Bisson, Denis Guillaneux, Didier Dubreuil
  • Patent number: 8680118
    Abstract: A compound of formula: wherein Ar1, Ar2, V, X, R3, R4, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 25, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Qun Sun, Laykea Tafesse
  • Publication number: 20140077175
    Abstract: A condensed-cyclic compound and an organic light-emitting diode including the condensed-cyclic compound.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 20, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jun-Ha Park, Eun-Young Lee, Chang-Ho Lee, Jong-Hyuk Lee
  • Publication number: 20140072517
    Abstract: Compounds and uses of the compounds are provided. The compounds can be used as Fe(II) sequestering compounds. For example, these compounds can be used to sequester Fe(II) in cells, organs, vasculature, or tissues. Also, provided are compositions and methods of using the them for sequestering Fe(II) in an individual. The compounds can be used as MRI paraCEST contrast agents.
    Type: Application
    Filed: May 11, 2012
    Publication date: March 13, 2014
    Applicant: The Research Foundation of State University of New
    Inventors: Janet Morrow, Pavel Tsitovich
  • Publication number: 20140061601
    Abstract: An anthracene compound and organic light emitting diode including the same are disclosed. The organic light emitting diode includes, at least two stacks formed between a first electrode and a second electrode and a charge generation layer (CGL) including an N-type CGL and a P-type CGL formed between the stacks, wherein the N-type CGL is formed of the anthracene compound.
    Type: Application
    Filed: December 26, 2012
    Publication date: March 6, 2014
    Applicant: LG DISPLAY CO., LTD.
    Inventors: Hyoseok KIM, Jeongdae SEO, Eunju JEON, Shinhan KIM
  • Patent number: 8653109
    Abstract: The present invention relates to novel substituted 2,4?- and 3,4?-bipyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: February 18, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Peter Nell, Walter Hübsch, Barbara Albrecht-Küpper, Joerg Keldenich, Andreas Knorr
  • Publication number: 20140034936
    Abstract: An organic compound having an excellent electron injection and transport performance is provided as a material for a low-power-consumption organic electroluminescent device. A low-power-consumption organic electroluminescent device is also provided by using the compound. The compound is a compound of general formula (1) or (2) having a substituted bipyridyl and triphenylene ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and uses the compound as constituent material of at least one of the organic layers.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 6, 2014
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, HODOGAYA CHEMICAL CO., LTD.
    Inventors: Chihaya Adachi, Kazunori Togashi, Norimasa Yokoyama, Shintaro Nomura
  • Publication number: 20140034935
    Abstract: A light-emitting-layer host material is provided as material for high-efficiency organic electroluminescent devices. The light-emitting-layer host material has a high excitation triplet level, and is capable of completely confining the triplet excitons of phosphorescent material. A high-efficiency and high-luminance organic electroluminescent device is provided by using the compound. The compound is a compound of general formula (1) having a bipyridyl group and an ortho-terphenyl structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and uses the compound as constituent material of at least one of the organic layers.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 6, 2014
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, Hodogaya Chemical Co., Ltd.
    Inventors: Chihaya Adachi, Takuma Yasuda, Kazunori Togashi, Shintaro Nomura
  • Publication number: 20140027754
    Abstract: The present invention provides a light emitting device material containing a compound having a specific pyrene structure, capable of providing an organic thin-film light emitting device which enables high-efficiency light emission and low-voltage driving, and is also excellent in durability; and a light emitting device using the same.
    Type: Application
    Filed: June 11, 2012
    Publication date: January 30, 2014
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Koji Ueoka, Kazumasa Nagao, Kazunori Sugimoto, Tsuyoshi Tominaga
  • Patent number: 8637548
    Abstract: A compound of formula: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: January 28, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Qun Sun, Xin Wen
  • Publication number: 20140024639
    Abstract: Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.
    Type: Application
    Filed: July 19, 2013
    Publication date: January 23, 2014
    Inventors: Drew Adams, Mingji Dai, Stuart Schreiber, Mahmud Mustaqim Hussain, Zarko Boskovic
  • Patent number: 8629164
    Abstract: The invention relates to compounds of formulae (1) and (2): and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: January 14, 2014
    Assignee: Profectus Biosciences, Inc.
    Inventors: Jie Zhang, Drago Robert Sliskovic, Charles E. Ducker